The Lymphoma Channel: CNS Lymphoma

Explore the latest updates and expert interviews

The Lymphoma Channel on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company), Takeda, Karyopharm Therapeutics and MorphoSys. The supporters have no influence over the production of the content.

Welcome to The CNS Lymphoma Channel

VJHemOnc brings you the most up-to-date developments within CNS lymphoma from key international congresses, where we offer exclusive video interviews, podcasts, and roundtable discussions with leading experts. The CNS Lymphoma Channel provides insightful perspectives on the latest trial updates and real-world data in CNS lymphoma.

View Lymphoma Overview Page
Insights into the diagnosis of primary CNS lymphoma and challenges in this space 1:26
Insights into the diagnosis of primary CNS lymphoma and challenges in this space
Gareth Gregory • 11 Dec 2022
Investigating the efficacy of CD20 CAR-T cell therapy for WM and CNS lymphoma 0:57
Investigating the efficacy of CD20 CAR-T cell therapy for WM and CNS lymphoma
Mazyar Shadman • 9 Dec 2022
The importance of circulating tumor DNA in patients with primary CNS lymphoma 1:03
The importance of circulating tumor DNA in patients with primary CNS lymphoma
Won-Seog Kim • 11 Jun 2022
Updates from the lymphoma & CLL session: clinical trials, novel agents, and more 7:50
Updates from the lymphoma & CLL session: clinical trials, novel agents, and more
Andrew Davies et al. • 4 Apr 2022
Efficacy & toxicity of CAR-T therapy in patients with secondary CNS involvement 1:06
Efficacy & toxicity of CAR-T therapy in patients with secondary CNS involvement
Nirav Niranjan Shah • 23 Apr 2022
The role of CAR-T therapy in primary and secondary CNS lymphoma 1:57
The role of CAR-T therapy in primary and secondary CNS lymphoma
Muhammad Husnain • 24 Apr 2022
Emerging CD19-targeted CAR-T treatment approaches for NHLs 1:26
Emerging CD19-targeted CAR-T treatment approaches for NHLs
Ulrich Jäger • 3 Feb 2022
The latest research in primary CNS lymphoma 5:53
The latest research in primary CNS lymphoma
Lakshmi Nayak • 17 Aug 2021
IELSG32 trial: 88-month follow-up on MATRIX followed by auto-SCT in primary CNS lymphoma 7:00
IELSG32 trial: 88-month follow-up on MATRIX followed by auto-SCT in primary CNS lymphoma
Andrés Ferreri • 9 Jun 2021
Thiotepa-containing regimens for PCNSL patients undergoing autoHCT 2:34
Thiotepa-containing regimens for PCNSL patients undergoing autoHCT
Trent Wang • 4 Dec 2020
Secondary CNS lymphoma: recent data and future approaches 14:09
Secondary CNS lymphoma: recent data and future approaches
Kate Cwynarski • 22 Jun 2020
Outcomes of older patients with primary CNS lymphoma 9:35
Outcomes of older patients with primary CNS lymphoma
Nicolas Martinez-Calle • 14 May 2020
CD19 CAR-T for CNS lymphoma 1:39
CD19 CAR-T for CNS lymphoma
Tanya Siddiqi • 7 Dec 2019
Real world data for axi-cel in lymphoma with secondary CNS involvement 3:59
Real world data for axi-cel in lymphoma with secondary CNS involvement
Yi Lin • 8 Dec 2019
Possibilities for the use of pembrolizumab in lymphoma treatment 1:36
Possibilities for the use of pembrolizumab in lymphoma treatment
John Kuruvilla
Nuances of systemic lymphoma and CNS lymphoma 1:01
Nuances of systemic lymphoma and CNS lymphoma
Bianca Santomasso • 21 Sep 2018

The Lymphoma Channel on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company), Takeda, Karyopharm Therapeutics and MorphoSys.

The supporters have no influence over the production of the content.

If you are interested in becoming a supporter of The Lymphoma Channel, please contact us.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals